Classification diagnostic kit for liver cancer Sorafenib personalized treatment

A sorafenib and kit technology, which is applied in the field of sorafenib personalized treatment of liver cancer typing diagnostic kits, can solve problems such as no reports of Gankyrin sorafenib combined with hydroxychloroquine molecular diagnostic kits.

Active Publication Date: 2014-08-06
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there are many reports about Gankyrin in the development and occurrence of liver cancer, but s

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Classification diagnostic kit for liver cancer Sorafenib personalized treatment
  • Classification diagnostic kit for liver cancer Sorafenib personalized treatment
  • Classification diagnostic kit for liver cancer Sorafenib personalized treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0160] Example 1. Overexpression of Gankyrin promotes the survival of liver cancer cells stimulated by Sorafenib

[0161] The SMMC-7721-luc or SMMC-7721-Gank cell lines were stimulated with 20uM Sorafenib for 24, 48, 72 hours or after 24 hours with different concentrations of Sorafenib (5uM, 10uM, 20uM), and the live cells number detection.

[0162] The result is as figure 1 As shown, it was found that overexpression of Gankyrin can promote the survival of liver cancer cells stimulated by Sorafenib.

Embodiment 2

[0163] Example 2, the effect of overexpressing Gankyrin or interfering with Gankyrin on apoptosis induced by Sorafenib

[0164] After the control cell line SMMC-7721-luc or the Gankyrin overexpression cell line SMMC-7721-Gank were stimulated with 20 uM Sorafenib (Sorafenib) for the corresponding time, the protein expression level of the PARP splice body was detected. The result is as figure 2 As shown in A, it was found that overexpression of Gankyrin can inhibit the increase of apoptotic splice body induced by sorafenib.

[0165] The HCC-LM3 cell line was treated with control adenovirus (Ad-GFP) or Gankyrin-interfering adenovirus (Ad-siGank), stimulated with 20 uM Sorafenib (Sorafenib) for a corresponding period of time, and the protein expression level of the corresponding molecule was detected. The result is as figure 2 As shown in B, it was found that interfering with Gankyrin can promote cell apoptosis induced by Sorafenib.

[0166] After the SMMC-7721-luc or SMMC-77...

Embodiment 3

[0167] Example 3. After inhibiting autophagy by chloroquine or 3-MA, Gankyrin can no longer inhibit the apoptosis caused by Sorafenib

[0168] After the SMMC-7721-luc / SMMC-7721-Gank cell line was stimulated by 20uM Sorafenib (Sorafenib) combined with CQ (chloroquine, Chloroquine) / 3-MA (3-methyladenine, 3-Methyladenine) for the corresponding time , to detect the number of viable cells. The result is as image 3 As shown in A.

[0169] SMMC-7721-luc / SMMC-7721-Gank cell line stimulated 24 hours after 20uM Sorafenib (Sorafenib) combined with CQ (chloroquine, Chloroquine) / 3-MA (3-methyladenine, 3-Methyladenine) , Western blotting to detect the expression of PARP splicing body. The result is as image 3 Shown in B.

[0170] After the SMMC-7721-luc / SMMC-7721-Gank cell line was stimulated by 20uM Sorafenib (Sorafenib) combined with CQ (chloroquine, Chloroquine) / 3-MA (3-methyladenine, 3-Methyladenine) for the corresponding time , Annexin V detected the proportion of apoptotic cel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a classification diagnostic kit for liver cancer Sorafenib personalized treatment. Gankyrin overexpression can obviously restrain cell death and subcutaneous tumor proliferation, caused by Sorafenib, but if hydroxychloroquine is combined, drug resistant reaction caused by Gankyrin overexpression is obviously restrained. The classification diagnostic kit can provide new reference for Sorafenib clinical application.

Description

technical field [0001] The invention relates to the field of biomedicine; more specifically, the invention relates to a typing diagnostic kit for sorafenib personalized treatment of liver cancer. Background technique [0002] Primary liver cancer (referred to as liver cancer) is the sixth most common malignant tumor in the world, with more than 700,000 new cases every year, of which hepatocellular carcinoma accounts for about 80%. Liver cancer is the most common malignant tumor in my country. New cases of liver cancer each year in China account for about 55% of the global total. Liver cancer is also the second leading cause of cancer-related deaths in my country. So far, surgical resection is still the best treatment for liver cancer, and it is also the first choice for early liver cancer. However, due to the insidious onset and rapid development of primary liver cancer, only about 10% of them can be surgically resected at the time of diagnosis. Even if surgery is performed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68
CPCA61K48/005G01N33/94G01N2800/52
Inventor 王红阳陈瑶罗韬付静谈冶雄
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap